ORIGINAL ARTICLES   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2003 August;162(4):91-6

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: Italian

Calcic nadroeparin in the prevention of thromboembolism in patients submitted to cesarean section

Cipriano L., Di Lillo A., Brosio F., Meloni P., Gioia S., Berta S., Pacifici E., Anceschi M. M.

Dipartimento di Scienze Ginecologiche, Perinatologia e Puericultura, Università degli Studi di Roma «La Sapienza», Roma

Aim. The aim of this paper is to study the efficacy of calcic nadroeparin, a low molecular weight heparin, for the prevention of venous thrombotic events occurring after cesarean section.
Methods. Between January 1 2001, to July 1 2002, a total of 66 patients who underwent a cesarean section, received calcic nadroeparin.
Hematological parameters were measured pre
operatively and on postoperative day 3.
Results. Of the 66 patients, 44 (67%) received 0.3 UI/ml calcic nadroeparin and 22 (33%), 0.4 UI/ml. The first dose of drug was administered in 34 (52%) patients intraoperatively, in 20 (30%) 4 hours, in 2 (3%) 8 hours and in 10 (15%) 12 hours postoperatively. The drug was given subcutaneously once daily for 5 or 8 days postoperatively. No significative variations of pre- and postoperative hematological parameters (PLT count, APTT, PT) were observed. No deep vein thrombosis, pulmonary embolism or infective complications occurred in any patients. All study patients were contactable at 2 and 6 weeks after cesarean section, and no thromboembolic complication was observed.
Conclusions. Deep vein thrombosis and pulmonary embolism are significant cause of post-operative morbidity and mortality in obstetric patients. Our study showed the importance of low-molecular-weight heparin (nadroeparin) in the prevention of thromboembolic events after cesarean section.